- Home
- YDKG vs XFOR Comparison
YDKG vs XFOR Comparison
Compare YDKG & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YDKG
- XFOR
- Stock Information
- Founded
- YDKG 2005
- XFOR 2014
- Country
- YDKG China
- XFOR United States
- Employees
- YDKG N/A
- XFOR N/A
- Industry
- YDKG Advertising
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YDKG Consumer Discretionary
- XFOR Health Care
- Exchange
- YDKG Nasdaq
- XFOR Nasdaq
- Market Cap
- YDKG 99.8M
- XFOR 84.3M
- IPO Year
- YDKG N/A
- XFOR N/A
- Fundamental
- Price
- YDKG $0.07
- XFOR $3.85
- Analyst Decision
- YDKG
- XFOR Strong Buy
- Analyst Count
- YDKG 0
- XFOR 3
- Target Price
- YDKG N/A
- XFOR $34.17
- AVG Volume (30 Days)
- YDKG 156.4M
- XFOR 1.4M
- Earning Date
- YDKG 11-17-2025
- XFOR 11-12-2025
- Dividend Yield
- YDKG N/A
- XFOR N/A
- EPS Growth
- YDKG N/A
- XFOR N/A
- EPS
- YDKG N/A
- XFOR N/A
- Revenue
- YDKG $13,107,000.00
- XFOR $32,774,000.00
- Revenue This Year
- YDKG N/A
- XFOR $1,307.51
- Revenue Next Year
- YDKG N/A
- XFOR N/A
- P/E Ratio
- YDKG N/A
- XFOR N/A
- Revenue Growth
- YDKG 2175.52
- XFOR 5721.31
- 52 Week Low
- YDKG $0.04
- XFOR $1.35
- 52 Week High
- YDKG $4.72
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- YDKG N/A
- XFOR 59.53
- Support Level
- YDKG N/A
- XFOR $2.96
- Resistance Level
- YDKG N/A
- XFOR $4.54
- Average True Range (ATR)
- YDKG 0.00
- XFOR 0.26
- MACD
- YDKG 0.00
- XFOR 0.05
- Stochastic Oscillator
- YDKG 0.00
- XFOR 49.51
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.